Alpine Bank Wealth Management Acquires Shares of 3,245 The Clorox Company (NYSE:CLX)

Alpine Bank Wealth Management purchased a new position in shares of The Clorox Company (NYSE:CLX - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 3,245 shares of the company's stock, valued at approximately $478,000.

Several other institutional investors also recently modified their holdings of the business. Golden State Wealth Management LLC increased its holdings in Clorox by 101.8% in the first quarter. Golden State Wealth Management LLC now owns 1,001 shares of the company's stock valued at $148,000 after purchasing an additional 505 shares during the last quarter. Spire Wealth Management grew its position in shares of Clorox by 133.4% during the 1st quarter. Spire Wealth Management now owns 873 shares of the company's stock worth $129,000 after buying an additional 499 shares during the period. Golden State Equity Partners acquired a new stake in shares of Clorox in the 1st quarter valued at approximately $430,000. Lecap Asset Management Ltd. raised its position in shares of Clorox by 540.4% in the 1st quarter. Lecap Asset Management Ltd. now owns 18,643 shares of the company's stock valued at $2,745,000 after acquiring an additional 15,732 shares during the period. Finally, International Assets Investment Management LLC boosted its stake in Clorox by 0.8% during the 1st quarter. International Assets Investment Management LLC now owns 103,156 shares of the company's stock worth $15,190,000 after acquiring an additional 830 shares during the last quarter. Institutional investors and hedge funds own 78.53% of the company's stock.

Clorox Stock Down 1.2%

Clorox stock traded down $1.45 during midday trading on Thursday, reaching $118.03. The stock had a trading volume of 1,829,014 shares, compared to its average volume of 1,368,834. The stock has a market capitalization of $14.55 billion, a P/E ratio of 21.19, a price-to-earnings-growth ratio of 2.70 and a beta of 0.54. The firm's fifty day simple moving average is $132.05 and its 200-day simple moving average is $145.95. The company has a debt-to-equity ratio of 13.07, a quick ratio of 0.44 and a current ratio of 0.74. The Clorox Company has a 1-year low of $117.38 and a 1-year high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 9.89% and a return on equity of 324.23%. Clorox's revenue for the quarter was down 8.0% on a year-over-year basis. During the same quarter last year, the business earned $1.71 earnings per share. As a group, analysts expect that The Clorox Company will post 7.15 EPS for the current fiscal year.

Insider Activity at Clorox

In related news, Director Pierre R. Breber acquired 4,000 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average price of $136.57 per share, with a total value of $546,280.00. Following the acquisition, the director now owns 4,000 shares in the company, valued at $546,280. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.57% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have commented on CLX shares. UBS Group lowered their target price on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Morgan Stanley lowered their price objective on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Jefferies Financial Group reduced their target price on Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a report on Thursday. JPMorgan Chase & Co. lowered their price target on Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Finally, Citigroup cut their price objective on Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a report on Monday, April 14th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Clorox presently has an average rating of "Hold" and a consensus target price of $149.50.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.